Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market Projected to Reach USD 28 Billion by 2033 at a 9.5% of CAGR

Castration-Resistant Prostate Cancer (CRPC) Treatment Market

The global castration-resistant prostate cancer (CRPC) treatment market is poised for substantial growth, expected to reach a market value of US$ 11.3 billion in 2023 and projected to surge to approximately US$ 28 billion by 2033. This represents a robust compound annual growth rate (CAGR) of 9.5% during the forecast period from 2023 to 2033. The market demonstrated steady growth in the historical period from 2018 to 2022, with a recorded CAGR of 6%.

The significant growth in the CRPC treatment market is primarily driven by the increasing prevalence of prostate cancer and the rising adoption of combination therapies to enhance treatment efficacy. As healthcare providers recognize the complexity of CRPC, there has been a shift towards integrated treatment approaches that combine various therapeutic modalities to improve patient outcomes and manage symptoms effectively.

North America remains the dominant region in the CRPC treatment market, supported by advanced healthcare infrastructure, high investment in cancer research, and a growing emphasis on personalized medicine. Meanwhile, the Asia-Pacific region is emerging as a key growth area, driven by increasing awareness of prostate cancer, improved diagnostic capabilities, and expanding access to innovative treatment options.

As the demand for effective CRPC therapies continues to rise, industry players are expected to focus on research and development, exploring new drug formulations, and fostering collaborations to enhance treatment options. The future of the castration-resistant prostate cancer treatment market looks promising, offering hope for improved patient management and outcomes in the fight against this challenging disease.

2018 to 2022 Castration-Resistant Prostate Cancer (CRPC) Treatment Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Castration-Resistant Prostate Cancer (CRPC) Treatment reflected a value of 6% during the historical period, 2018 to 2022.

Increasing prevalence of prostate cancer, the development of new therapies, and the rising demand for personalized medicine is driving the growth of the castration-resistant prostate cancer (CRPC) treatment market. Moreover, research and development along with technological integration for innovating medication is expected to bolster the demand for treatment of castration-resistant prostate cancer (CRPC) treatment market.

Thus, the market for Castration-Resistant Prostate Cancer (CRPC) Treatment is expected to register a CAGR of 9.5% in the forecast period 2023 to 2033.

Market Competition

Key players in the castration-resistant prostate cancer (CRPC) treatment market are Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC, Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc, Dendreon Corporation

• In 2018, Sanofi and Regeneron Pharmaceuticals announced the results of a phase 3 clinical trial investigating the use of their immunotherapy drug, cemiplimab, in combination with Jevtana for the treatment of metastatic CRPC. The trial showed promising results, with the combination therapy significantly improving overall survival and progression-free survival compared to Jevtana alone.
• In 2019, Pfizer announced the results of a phase 3 clinical trial investigating the use of Xtandi in combination with abiraterone acetate, another androgen receptor inhibitor, for the treatment of metastatic CRPC.

Key Companies Profiled

• Sanofi S.A.
• Johnson and Johnson
• Pfizer, Inc.
• Bayer AG
• Abbott Laboratories
• GlaxoSmithKline PLC
• Northwest Biotherapeutics, Inc.
• Active Biotech AB
• Astellas Pharma, Inc
• Dendreon Corporation

A Full Report Overview

Key Segments Profiled in the Castration-Resistant Prostate Cancer (CRPC) Treatment Industry Survey

Therapy Type:

• Hormonal therapy
• Chemotherapy
• Immunotherapy
• Radiotherapy

Drug Class:

• Antineoplastic
• Non-steroidal Antiandrogen
• Corticosteroids
• Microtubule Inhibitor

Drug Delivery Method:

• Oral Route
• Injectable Route

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• MEA

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube